And Sanofi's notice of appointing 3 Independent Directors yesterday, having already announced plans to spin-off their healthcare business, suggests preparations to ready the spin-off for Nasdaq listing.
And as Preciouslife1's article informed us today, "Novavax expects full-year 2024 revenue to come in between $800 million and $1 billion. That forecast reflects an expected $500 million to $600 million in revenue from advanced purchase agreements and $300 million to $400 million from commercial market product sales, royalties and other revenue from the company’s “partner-related activity.”
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.